Pomerantz LLP Investigates Claims Regarding bluebird bio, inc. on Behalf of Investors
NEW YORK, March 11, 2025
Pomerantz LLP, a leading securities law firm, is investigating potential claims on behalf of investors of bluebird bio, inc. (“bluebird” or the “Company”) (NASDAQ: BLUE). The investigation concerns whether bluebird and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
Background
bluebird is a clinical-stage biotechnology company dedicated to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer. The Company’s most advanced product candidate, LentiGlobin, is a gene therapy being developed for the treatment of beta-thalassemia and sickle cell disease. The Company’s other product candidates include Lenti-D, which is being investigated for the treatment of cerebral adrenoleukodystrophy, and bb2121, which is being investigated for the treatment of multiple myeloma.
The Investigation
The investigation concerns whether bluebird and certain of its executives and directors have made false and/or misleading statements and/or failed to disclose material information to the investing public. Specifically, the investigation focuses on certain statements made by the Company regarding the safety and efficacy of its LentiGlobin product candidate and its clinical trials.
Impact on Individual Investors
If you are a bluebird investor who purchased or otherwise acquired bluebird securities between [Date], and [Date], both dates inclusive, you may be entitled to recover your investment losses. Investors who suffer losses on their bluebird investments or who wish to inquire about potentially recoverable losses are encouraged to contact Pomerantz LLP, with significant experience in securities class actions.
Impact on the World
The potential securities fraud investigation against bluebird could have far-reaching consequences for the biotechnology industry as a whole. If it is found that bluebird and its executives and directors have engaged in fraudulent or deceptive practices, it could lead to increased scrutiny of other biotech companies and potentially undermine investor confidence in the sector. Furthermore, any damages awarded to investors could result in significant financial losses for the Company and its executives.
Conclusion
Pomerantz LLP is committed to advocating for the rights of investors, and we encourage investors with any information or inquiries regarding the bluebird investigation to contact us. While the outcome of any securities fraud investigation is uncertain, it is important for investors to be aware of the potential risks and to take action if they believe they have been harmed. As the investigation into bluebird continues, we will provide updates as new information becomes available.
- Pomerantz LLP is investigating potential claims against bluebird bio, inc.
- The investigation concerns potential securities fraud or other unlawful business practices.
- The focus of the investigation is on statements regarding the safety and efficacy of LentiGlobin and clinical trials.
- Individual investors who purchased bluebird securities between certain dates may be entitled to recover investment losses.
- The potential investigation could have significant consequences for the biotechnology industry and investor confidence.
